Hennion & Walsh Asset Management Inc. Purchases 426 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hennion & Walsh Asset Management Inc. lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.0% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,365 shares of the biopharmaceutical company’s stock after purchasing an additional 426 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,276,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in REGN. Vanguard Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock valued at $7,762,577,000 after acquiring an additional 39,780 shares in the last quarter. Capital World Investors boosted its holdings in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after acquiring an additional 23,146 shares in the last quarter. Putnam Investments LLC boosted its holdings in Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after acquiring an additional 24,329 shares in the last quarter. Norges Bank bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $932,571,000. Finally, Morgan Stanley lifted its position in Regeneron Pharmaceuticals by 2.7% during the third quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after buying an additional 25,792 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent research reports. UBS Group raised their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. Royal Bank of Canada reissued an “outperform” rating and set a $1,229.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, June 24th. Bank of America raised their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Finally, Truist Financial reissued a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,027.55.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $0.17 during trading hours on Friday, hitting $1,051.03. The company’s stock had a trading volume of 750,619 shares, compared to its average volume of 469,667. The company’s 50 day simple moving average is $984.27 and its two-hundred day simple moving average is $950.40. The company has a market cap of $115.81 billion, a P/E ratio of 31.05, a price-to-earnings-growth ratio of 2.17 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 12 month low of $688.52 and a 12 month high of $1,081.17. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,347,256.52. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Michael S. Brown sold 1,535 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,437,280. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The disclosure for this sale can be found here. Insiders sold a total of 61,971 shares of company stock worth $61,217,654 in the last three months. 7.48% of the stock is currently owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.